http://phys.org/ en-us Phys.org internet news portal provides the latest news on science including: Physics, Nanotechnology, Life Sciences, Space Science, Earth Science, Environment, Health and Medicine. The US Food and Drug Administration on Monday approved Incivek to treat hepatitis C when taken along with the current two-drug regimen, marking the second such drug approval this month. http://phys.org/news225363695.html Medicine & Health Mon, 23 May 2011 10:02:18 EST news225363695 US regulators on Friday approved the first new treatment for hepatitis C in more than a decade, a Merck pharmaceutical known as Victrelis, to be taken with the current two-drug regimen. http://phys.org/news224574559.html Medicine & Health Sat, 14 May 2011 06:49:54 EST news224574559 A US government advisory committee on Wednesday unanimously voted to urge the Food and Drug Administration to approve a new drug made by Merck to fight hepatitis C, a disease which attacks the liver. http://phys.org/news223139527.html Medicine & Health Wed, 27 Apr 2011 16:12:34 EST news223139527 Berlin, Germany, Saturday 02 April 2011: Exciting new data presented today at the International Liver CongressTM 2011 show that quadruple therapy in chronic hepatitis C (HCV) patients suppressed the emergence of resistant variants and resulted in a 100% rate of sustained virological response - undetectable HCV RNA - 12 weeks after treatment (SVR12).1 http://phys.org/news220986914.html Medicine & Health Sat, 02 Apr 2011 18:15:28 EST news220986914 Berlin, Germany, Friday 1st April 2011: Highly anticipated data from a number of clinical trials presented for the first time at the International Liver CongressTM confirmed that a range of new proteases inhibitors will help treat patients who have previously failed therapy for the treatment of chronic hepatitis C.1,2,3,4,5 http://phys.org/news220877286.html Medicine & Health Fri, 01 Apr 2011 11:48:28 EST news220877286 The drug boceprevir helps cure hard-to-treat hepatitis C, says Saint Louis University investigator Bruce R. Bacon, M.D., author of the March 31 New England Journal of Medicine article detailing the study's findings. The results, which were first reported at the 61st annual meeting of the American Association for the Study of Liver Disease's last November, offer a brighter outlook for patients who have not responded to standard treatment. http://phys.org/news220724722.html Medicine & Health Wed, 30 Mar 2011 18:30:01 EST news220724722 Researchers at Cedars-Sinai Medical Center and 50 other centers found that weight-based dosing of taribavirin reduces rates of anemia while increasing sustained virologic response (SVR) in patients with chronic hepatitis C (HCV). Full details of this study are available in the October issue of Hepatology. http://phys.org/news204368367.html Medicine & Health Wed, 22 Sep 2010 09:59:45 EST news204368367 Adding a direct acting anti-viral drug to the standard treatment regimen for hepatitis C significantly increases the cure rate in the most difficult to treat patients, according to a research report published Monday in the online edition of the journal The Lancet. http://phys.org/news200234595.html Medicine & Health Sun, 08 Aug 2010 18:30:01 EST news200234595 In patients with chronic hepatitis C, treatment with peginterferon alpha-2a (PegIFNα2a) plus ribavirin (RBV) better suppresses the virus to undetectable levels in the blood than treatment with peginterferon alpha-2b (PegIFNα2b) plus RBV, according to two new head-to-head studies in Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute. http://phys.org/news181838503.html Medicine & Health Mon, 04 Jan 2010 15:10:08 EST news181838503 Patients with chronic hepatitis C and advanced liver disease who drink three or more cups of coffee per day have a 53% lower risk of liver disease progression than non-coffee drinkers according to a new study led by Neal Freedman, Ph.D., MPH, from the National Cancer Institute (NCI). http://phys.org/news175261769.html Medicine & Health Tue, 20 Oct 2009 13:00:01 EST news175261769 It is still unknown why the natural history of chronic disease caused by hepatitis C virus (HCV), which currently infects 3% of the world's population, varies from mild in some patients to rapidly progressing in others. http://phys.org/news170518579.html Medicine & Health Wed, 26 Aug 2009 19:20:01 EST news170518579 Findings from the largest study to date comparing the efficacy of competing treatments for chronic hepatitis C infection (HCV) show that the regimens are similar when it comes to safety and their ability to provoke long-term viral eradication, according to researchers at Duke University Medical Center. Still, subgroup analysis reveals provocative data suggesting some approaches might be better than others for women and minorities. http://phys.org/news167502970.html Medicine & Health Wed, 22 Jul 2009 17:36:53 EST news167502970 Two new studies address donor factors that could affect outcomes for liver transplant recipients, particularly those with chronic hepatitis C (HCV). One found that donor steatosis, or fat in the liver, does not affect liver disease progression or three-year survival in recipients with or without HCV. However, transplants from people higher on the Donor Risk Index did adversely affect the outcomes of HCV-positive recipients more than recipients without HCV. http://phys.org/news162740009.html Medicine & Health Thu, 28 May 2009 14:33:52 EST news162740009 Patients with chronic hepatitis C that has been resolved through therapy or immune response may still be able to infect others with the virus. That finding is from a new study in the May issue of Hepatology, a journal published by John Wiley & Sons on behalf of the American Association for the Study of Liver Diseases (AASLD). http://phys.org/news160656818.html Medicine & Health Mon, 04 May 2009 11:53:52 EST news160656818